Ventilator Acquired Pneumonia
13
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
88.9%
+2.4% vs benchmark
8%
1 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Steriwave ICU Pilot Study
Evidence-Based Nursing to Reduce Adverse Events Regarding Ventilator Associated Pneumonia, Pressure Injuries and Central Line Bloodstream Infection in Intensive Care Unit in Bangladesh
ClusterVAP: Multicentre Proteomic Endotyping of Ventilator-associated Pneumonia
Effect of Use of Probiotics on Systemic Infection in Critically Ill Patients: a Double Blind, Randomized, Placebo-controlled Trial
Real-World Study of Ceftazidime Avibactam in China
Assessment of the Role of Probiotics in Prevention of Ventilator-Associated Pneumonia in Neonates
Intravenous Metoprolol in Septic Shock
Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia
Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients
Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients
Cost Effectiveness Of Linezolid In Central America
Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
Ontario ICU Clinical Best Practices Demonstration Project